Tests ordastobart with pembrolizumab in HPV-positive throat cancer that has returned or spread
Tests ordastobart added to pembrolizumab in adults with HPV-positive throat cancer.
Key facts
- Who runs it
- Inhibrx Biosciences, Inc
- Where
- Billings, Boston, Chapel Hill, Chicago, Corpus Christi, Detroit, Duarte, Gainesville, Las Vegas, Los Angeles, Louisville, Miami, Newark, Oklahoma City, Omaha, Orange City, Pittsburgh, Portland, Richmond, Sacramento, San Diego, Santa Fe, Santa Monica, St Louis, and Weston, United StatesSee the 26 sitesAlso in 12 other countries, 63 sites
- Trial code
- Registry title
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 450 people, planned
- Started
- 14 May 2024
- Expected to end
- May 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- INBRX-106
- Pembrolizumab
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose oropharyngeal cancer (throat cancer) is HPV-positive, has come back or spread, and cannot be cured with local treatment. The tumor must also express PD-L1.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Oropharyngeal squamous cell carcinoma that has come back or spread and cannot be cleared by local treatment. The disease must be measurable on scans (RECIST 1.1). Daily activity level (ECOG) must be 0 or 1.
- Earlier treatment
- No earlier systemic treatment (such as chemotherapy, immunotherapy or biologic therapy) for recurrent or metastatic disease. Earlier treatment given as part of treatment meant to remove all of the disease is allowed only under set time limits.
- Biomarker or test result
- PD-L1 combined proportion score (CPS) of 1 or higher by central testing. HPV-positive tumor by local p16 immunohistochemistry (IHC).
Main reasons for not taking part
- Primary tumor in any place other than the oropharynx
- Active brain metastases or cancer cells in the membranes around the brain (meningitis)
- Immunodeficiency, or steroid or other immune-suppressing treatment within 7 days before the first dose
- Rapidly progressing disease
- Active or high risk of tumor-related bleeding
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Has histologically or cytologically confirmed diagnosis of recurrent/metastatic oropharyngeal squamous cell carcinoma (OPSCC) considered incurable by local therapies
- Has tumor PD-L1 expression with a combined proportion score (CPS) ≥1 by central testing
- HPV-positive tumor status as assessed locally by p16 immunohistochemistry (IHC)
- Has measurable disease per RECIST 1.1 guidelines
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Who cannot take part
- Has received prior systemic therapy (eg, prior chemo-, immune-, or biologic therapy) for R/M HNSCC; Prior systemic therapy completed >6 months prior to signing informed consent is allowed if given as part of multimodal treatment for locoregionally advanced disease with curative intent, and no PD/recurrence occurred within 6 months of its completion. Prior systemic immunotherapy with curative intent, including but not limited to anti-PD-(L)1 agents, is allowed if PD/recurrence occurred ≥12 months after its completion
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
- Rapidly progressing disease
- Active or high risk of tumor-associated bleeding
- Current or history of immune-related disease that required systemic treatment in past 2 years, except for replacement therapy
- Has primary tumor site (any histology) of any other location than oropharynx
- Has clinically active central nervous system metastases and/or carcinomatous meningitis
Where in United States
Also in 12 other countries, 63 sites
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of MontanaBillings, United StatesContact: Patrick Cobb, MD (principal investigator)Taking people
- Massachusetts General HospitalBoston, United StatesContact: Study Director - InhibrxNo longer taking part
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Jonathan JacksonTaking people
- University of Illinois Cancer CenterChicago, United StatesContact: Annette KinsellaTaking people
- CHRISTUS Spohn Cancer CenterCorpus Christi, United StatesContact: Swetha Panati, MD (principal investigator)Taking people
- Karmanos Cancer InstituteDetroit, United StatesContact: Ammar Sukari, MD (principal investigator)Taking people
- City of Hope Medical CenterDuarte, United StatesContact: Victoria M Villaflor, MD (principal investigator)Taking people
- University of Florida UF Health Cancer CenterGainesville, United StatesContact: Study Director - InhibrxNo longer taking part
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesContact: Ann LovelaceTaking people
- Los Angeles Cancer Network (LACN)Los Angeles, United StatesContact: Sungwon Rachel Kyung, MD (principal investigator)Taking people
- Norton Cancer InstituteLouisville, United StatesContact: Jaspreet Grewal, MD (principal investigator)Taking people
- The Oncology Institute of Hope & InnovationMiami, United StatesContact: Edgardo Santos, MD (principal investigator)Taking people
- ChristianaCare Health ServicesNewark, United StatesContact: Study Director - InhibrxNo longer taking part
- Oklahoma University-Stephenson Cancer CenterOklahoma City, United StatesContact: Shae Pfenning, RNTaking people
- Oncology Hematology West, PC dba Nebraska Cancer SpecialistsOmaha, United StatesContact: Yungpo B. Su, MD (principal investigator)Taking people
- Mid Florida Hematology and oncology CenterOrange City, United StatesContact: Santosh Nair, MD (principal investigator)Taking people
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Jennifer RuthTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Study Director - InhibrxNo longer taking part
- VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Elisabeth HolmesTaking people
- Sutter HealthSacramento, United StatesContact: Study Director - InhibrxNo longer taking part
- UC DavisSacramento, United StatesContact: Study Director - InhibrxNo longer taking part
- Medical Oncology Associates of San DiegoSan Diego, United StatesContact: Amanda SomoTaking people
- CHRISTUS St. Vincent Regional Cancer CenterSanta Fe, United StatesContact: Andrea Teague, MD (principal investigator)Taking people
- Sarcoma Oncology CenterSanta Monica, United StatesContact: Neal Chawla, MD (principal investigator)Taking people
- Washington University St. LouisSt Louis, United StatesContact: Jesse Zaretsky, MD (principal investigator)Taking people
- Cleveland Clinic Florida, The Maroone Cancer CenterWeston, United StatesContact: Study Director - InhibrxNo longer taking part
About the trial
What the trial wants to find out
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with recurrent or metastatic (R/M) HPV-positive Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) expressing PD-L1.
The 2 groups in the trial
- ordastobart (INBRX-106) plus pembrolizumabTreatment being tested
Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3)
Treatment: INBRX-106 and Pembrolizumab
- pembrolizumab monotherapy (+ placebo in phase 3 part)Existing treatment, for comparison
Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3)
Treatment: Pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2/3, Randomized Study of Ordastobart (INBRX-106) Plus Pembrolizumab vs Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma Expressing PD-L1 (HexAgon-HN)
- Plain-language title
- Tests ordastobart with pembrolizumab in HPV-positive throat cancer that has returned or spreadGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 October 2026